Tempest Therapeutics (TPST) Cash from Investing Activities (2012 - 2024)
Tempest Therapeutics (TPST) posted Cash from Investing Activities of -$3000.0 for Q4 2024, up 80.0% sequentially from -$15000.0 in Q3 2024, and up 57.14% YoY from -$1909.1 in Q1 2024.
Tempest Therapeutics (TPST) Cash from Investing Activities (2012 - 2024) Analysis & Trends
Tempest Therapeutics has reported Cash from Investing Activities for 13 years, with the latest figure at -$3000.0 in Q4 2024.
- Quarterly Cash from Investing Activities rose 57.14% year-over-year to -$3000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$3000.0 (up 99.32% YoY) and the FY2024 annual result came in at -$435000.0, down 155.88% from the prior year.
- Cash from Investing Activities rose to -$3000.0 in Q4 2024 per TPST's latest filing, from -$15000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $33000.0 in Q2 2020 and troughed at -$356000.0 in Q4 2022.
- A 5-year average of -$66842.1 and a median of -$26000.0 in 2020 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2021 and 2023: Cash from Investing Activities jumped 275.0% in 2021, then slumped 1433.33% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$5000.0 in 2020, then slumped by 440.0% to -$27000.0 in 2021, then slumped by 1218.52% to -$356000.0 in 2022, then jumped by 98.03% to -$7000.0 in 2023, then jumped by 57.14% to -$3000.0 in 2024.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$3000.0, -$15000.0, and -$249000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Sep 30, 2024 | -15,000.00 |
| Sep 30, 2024 | -15,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -168,000.00 |
| Mar 31, 2024 | -168,000.00 |
| Dec 31, 2023 | -7,000.00 |
| Dec 31, 2023 | -7,000.00 |
| Jun 30, 2023 | -117,000.00 |
| Jun 30, 2023 | -117,000.00 |
| Mar 31, 2023 | -46,000.00 |
| Mar 31, 2023 | -46,000.00 |
| Dec 31, 2022 | -356,000.00 |
| Dec 31, 2022 | -356,000.00 |
| Sep 30, 2022 | -108,000.00 |
| Sep 30, 2022 | -108,000.00 |
| Jun 30, 2022 | -95,000.00 |
| Jun 30, 2022 | -95,000.00 |